drugset / Trial / NCT01503515

Caspofungin Acetate, Fluconazole, or Voriconazole in Preventing Fungal Infections in Patients Following Donor Stem Cell Transplant

NCT01503515

RandomizedParallel-groupOpen-labelSupportive care

Summary

This randomized phase III trial studies how well caspofungin acetate works compared to fluconazole or voriconazole in preventing fungal infections in patients following donor stem cell transplant. Caspofungin acetate, fluconazole, and voriconazole may be effective in preventing fungal infections in patients following donor stem cell transplant. It is not yet known whether caspofungin acetate is more effective than fluconazole or voriconazole in preventing fungal infections in patients following donor stem cell transplant.

Timeline

Start
2013-03-21
Primary completion
2019-12-31
Completion
2021-09-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Caspofungin Other / unclassified Intravenous
Comparator Fluconazole Small molecule Intravenous
Comparator Voriconazole Small molecule Intravenous